|
Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >
Real-world safety and effectiveness of nivolumab for advanced renal cell carcinoma in Japan : a post-marketing surveillance
Title: | Real-world safety and effectiveness of nivolumab for advanced renal cell carcinoma in Japan : a post-marketing surveillance |
Authors: | Uemura, Hirotsugu Browse this author →KAKEN DB | Tomita, Yoshihiko Browse this author →KAKEN DB | Nonomura, Norio Browse this author →KAKEN DB | Yoshizaki, Kenji Browse this author | Nakao, Takafumi Browse this author →KAKEN DB | Shinohara, Nobuo Browse this author →KAKEN DB |
Keywords: | Effectiveness | Japan | Nivolumab | Post-marketing surveillance | Safety | Un-resectable or metastatic renal cell carcinoma |
Issue Date: | 20-Apr-2022 |
Publisher: | Springer |
Journal Title: | International journal of clinical oncology |
Volume: | 27 |
Start Page: | 1061 |
End Page: | 1067 |
Publisher DOI: | 10.1007/s10147-022-02155-3 |
Abstract: | Background This all-case post-marketing surveillance (PMS) evaluated the real-world safety and effectiveness of nivolumab monotherapy in Japanese patients with un-resectable or metastatic renal cell carcinoma (RCC). Methods This multicenter, open-label, non-interventional, observational PMS study (registered from August 2016 to January 2017) was conducted in patients who were newly initiated on nivolumab monotherapy. Assessments included treatment-related adverse events (TRAEs) of special interest, patient characteristics affecting safety, and effectiveness over 12 months. Results Overall, 580 patients were enrolled; 555 and 554 patients comprised the safety and effectiveness analysis sets, respectively. The median (range) age of the population was 66 (14-90) years. Nivolumab was initiated as 1st-, 2nd-, and >= 3rd-line treatment in 0.2%, 42.0%, and 57.8% of patients, respectively. TRAEs were reported in 275 (49.5%) patients. The most common TRAEs of special interest included thyroid dysfunction (9.5%), hepatic dysfunction (8.6%), and interstitial lung disease (6.7%). The incidence of TRAEs was significantly higher in elderly patients (>= 65 vs < 65 years; >= 75 vs < 75 years); patients with lower C-reactive protein levels (< 5 vs >= 5 mg/dL); and patients with vs without a past medical history, including hepatic, thyroid, and autoimmune diseases. The 6- and 12-month survival rates were 71.8% and 57.9%, respectively. Conclusion The safety profile of nivolumab monotherapy in Japanese patients with advanced RCC was similar to that in the phase 3 CheckMate 025 trial. No new safety signals were observed in this study. |
Type: | article |
URI: | http://hdl.handle.net/2115/85543 |
Appears in Collections: | 医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
|